Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.
View Top Employees from ProtheliaWebsite | http://www.prothelia.com |
Revenue | $5 million |
Employees | 3 (3 on RocketReach) |
Founded | 2008 |
Address | 30 Haven St, Milford, Massachusetts 01757, US |
Phone | (508) 561-9298 |
Fax | (508) 276-0475 |
Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering |
Competitors | PTC Therapeutics, Inc., Santhera Pharmaceuticals, Sarepta Therapeutics, Strongbridge Biopharma plc, Tarix Pharmaceuticals LTD. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies |
Looking for a particular Prothelia employee's phone or email?
The Prothelia annual revenue was $5 million in 2024.
3 people are employed at Prothelia.
Prothelia is based in Milford, Massachusetts.
The NAICS codes for Prothelia are [54, 5417, 54171, 541, 541714].
The SIC codes for Prothelia are [87, 873].